Medical Condition News

RSS

Researchers discover new gene regulation, DNA behavior of breast cancer cells

Cancer researchers have discovered a previously unknown type of gene regulation and DNA behavior in breast cancer cells that may lead to better insight about environmental exposure to estrogen-like compounds. A new study, published in the journal Genome Research by researchers at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), provides the first evidence that cells can regulate many genes at once by looping their DNA, contributing to cancer when it goes awry. In this study, the gene regulation was discovered in breast cancer cells as a response to the hormone estrogen and resulted in the silencing of 14 genes at one time.

20 Jul 2010

John Theurer Cancer Center to acquire TrueBeam system for treating cancer patients

In a promising development for cancer patients in New Jersey and surrounding areas, the John Theurer Cancer Center at Hackensack University Medical Center announced today that it will be the first cancer center in New Jersey to acquire an innovative system that enables a radically different approach to treating cancer with image-guided radiotherapy known as the TrueBeam- system.

20 Jul 2010

Researchers discover genetic explanation for non-diabetic kidney disease in African-Americans

Kidney disease is a growing public health problem, with approximately half a million individuals in the United States requiring dialysis treatments to replace the function of their failed kidneys. The problem is particularly acute among African-Americans, whose rates of kidney disease are four times higher than those of European Americans.

20 Jul 2010

Researchers identify a mechanism that explains different phases of CML progression

Researchers at Duke University Medical Center have identified a mechanism that could explain how patients move into the worst phase of chronic myelogenous leukemia.

20 Jul 2010

Benefits of drug L-methionine for neurogenic bladder disorders unclear

It is unclear whether patients with neurogenic bladder disorders benefit from the drug L-methionine. The only study currently available provides neither proof of benefit nor proof of harm. This is the result of a report published by the German Institute for Quality and Efficiency in Health Care (IQWiG) on 12 July 2010.

20 Jul 2010

Researchers monitor stress during a real-time war to refine PTSD therapy

Psychologists aren't usually called to the battlefield, but the 2008-09 Gaza War gave Tel Aviv University researchers a unique picture of how anxiety manifests during stressful situations.

20 Jul 2010

DEKA Medical announces availability of new SmartXide DOT HP Fractional CO2 laser

DEKA Medical announced today the immediate availability of the High-Powered SmartXide DOT. The new SmartXide DOT HP Fractional CO2 laser, with average power of 50W, can attain irradiance of up to 250W of power with each pulse. This makes the new SmartXide DOT HP the most powerful superpulse CO2 laser available to aesthetic physicians.

19 Jul 2010

Amira achieves two clinical development milestones in FLAP program for asthma

"Amira Pharmaceuticals, Inc. announced today that its FLAP (5-lipoxygenase-activating protein) program, which is partnered with GlaxoSmithKline, has achieved two clinical development milestones."

19 Jul 2010

IBA Dosimetry to showcase Blue Phantom[2] radiation therapy commissioning solution with LDA-99SC at AAPM

IBA Dosimetry, member of IBA Group, will showcase its latest innovation in radiation therapy commissioning solutions, the Blue Phantom[2] water phantom equipped with advanced Linear Diode Array technology (LDA-99SC), at the American Association of Physicists in Medicine Annual Meeting in Philadelphia, July 18 - 22, 2010.

19 Jul 2010

Oncolytics Biotech receives Canadian approval for combination REOLYSIN Phase 3 trial in head, neck cancer

Oncolytics Biotech Inc. today announced that it has received a No Objection Letter from Health Canada to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.

19 Jul 2010

Geron commences enrollment in imetelstat Phase 2 clinical trial for NSCLC

Geron Corporation today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), as maintenance therapy following platinum-based induction therapy for patients with non-small cell lung cancer (NSCLC).

19 Jul 2010

Biosystems International closes EUR2.1 million funding round

Biosystems International (BSI) SAS, Biotech Leader in the Development of Monoclonal Antibody Based Diagnostics for Cancer, Announced Today That it has Closed a Round of Funding Amounting to EUR2.1 Million ($2.7 Million).

19 Jul 2010

FDA approves Mylan's ANDA for generic Catapres-TTS

Mylan Inc. today announced that its subsidiary Mylan Technologies Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clonidine Transdermal System USP, 0.1 mg/day, 0.2 mg/day and 0.3 mg/day, the generic version of Boehringer Ingelheim's Catapres-TTS®, a treatment for hypertension.

19 Jul 2010

Novo Nordisk recruits 60,000th patient in world's largest observational study in insulin therapy

Today, Novo Nordisk announced the landmark recruitment of the 60,000th patient in the A1chieve(R) study - an observational study designed to investigate the effects of modern insulins in the management of type 2 diabetes.

From Novo Nordisk 19 Jul 2010

Over-expression of CIB1 protein triggers biochemical processes that lead to cardiac hypertrophy: Study

Scientists have identified a key molecular regulator of cardiac hypertrophy (enlargement of the heart) that may provide a therapeutic target for a major risk factor of heart failure and early death.

19 Jul 2010

Brain cancer survivor completes journey across America to raise awareness, money for brain cancer research

Anne Feeley, a 56-year-old mother and brain cancer survivor, completed her journey across America today, cycling 3,708 miles, to raise awareness and money for brain cancer research and patient care. Feeley pedaled the last 6.5 miles of her journey from Hains Point, VA to cross the finish line at the Capital Reflecting Pool in Washington, DC.

19 Jul 2010

Olig1 and Olig2 genes are associated with Down syndrome, scientists identify

Down syndrome is a well known cause of mental retardation and other medical problems, including early onset of Alzheimer disease. It has long been known that Down syndrome is associated with an individual having an additional copy of chromosome 21. Research findings reported in the July 18 advanced online publication of Nature Neuroscience have narrowed down the critical genetic elements responsible for some aspects of Down syndrome.

19 Jul 2010

AHRQ: 12M people with mental health, substance abuse problems visited emergency department in 2007

Nearly 12 million visits made to U.S. hospital emergency departments in 2007 involved people with a mental disorder, substance abuse problem, or both, according to the latest News and Numbers from the Agency for Healthcare Research and Quality. This accounts for one in eight of the 95 million visits to emergency departments by adults that year.

17 Jul 2010

Low-dose method of performing CT heart scans developed at Porter Adventist Hospital

As warnings and concern increase over the health risks of commonly used scanning tests involving high doses of radiation, radiologists and scientists are seeking ways to improve the safety of the tools they use in diagnosing disease.

17 Jul 2010

GABA disrupts working memory in neurofibromatosis type 1 patients

Imagine if your brain lost its working memory - the ability to hold and manipulate information in your mind's eye. That's the plight faced by millions of people with neurofibromatosis type 1, or NF1. The genetic condition affects one in 3,500 people and is the most common cause of learning disabilities.Now a UCLA research team has uncovered new clues about how NF1 disrupts working memory. Published in the July 12 online edition of Proceedings of the National Academy of Sciences, the findings suggest a potential drug target for correcting NF1-related learning disabilities.

17 Jul 2010

Medical Condition News

Researchers discover new gene regulation, DNA behavior of breast cancer cells

John Theurer Cancer Center to acquire TrueBeam system for treating cancer patients

Researchers discover genetic explanation for non-diabetic kidney disease in African-Americans

Researchers identify a mechanism that explains different phases of CML progression

Benefits of drug L-methionine for neurogenic bladder disorders unclear

Researchers monitor stress during a real-time war to refine PTSD therapy

DEKA Medical announces availability of new SmartXide DOT HP Fractional CO2 laser

Amira achieves two clinical development milestones in FLAP program for asthma

IBA Dosimetry to showcase Blue Phantom[2] radiation therapy commissioning solution with LDA-99SC at AAPM

Oncolytics Biotech receives Canadian approval for combination REOLYSIN Phase 3 trial in head, neck cancer

Geron commences enrollment in imetelstat Phase 2 clinical trial for NSCLC

Biosystems International closes EUR2.1 million funding round

FDA approves Mylan's ANDA for generic Catapres-TTS

Novo Nordisk recruits 60,000th patient in world's largest observational study in insulin therapy

Over-expression of CIB1 protein triggers biochemical processes that lead to cardiac hypertrophy: Study

Brain cancer survivor completes journey across America to raise awareness, money for brain cancer research

Olig1 and Olig2 genes are associated with Down syndrome, scientists identify

AHRQ: 12M people with mental health, substance abuse problems visited emergency department in 2007

Low-dose method of performing CT heart scans developed at Porter Adventist Hospital

GABA disrupts working memory in neurofibromatosis type 1 patients

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News